Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bosentan→

Bosentan Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
147536-97-8
Molecular formula
C27H29N5O6S
Molecular weight
551.6 g/mol
Drug class
Dual endothelin receptor antagonist (ERA)vasodilator for pulmonary arterial hypertension
Mechanism of action
Competitively antagonises endothelin ETA and ETB receptors. This reduces endothelin-mediated vasoconstriction and proliferative effects in pulmonary vascular smooth muscle, lowering pulmonary vascular resistance.
Indications / reported uses
  • Treatment of pulmonary arterial hypertension (PAH) to improve exercise ability and reduce clinical worsening in eligible adults and paediatric patients; current age, functional-class and monitoring criteria are product-label specific

Sources: US DailyMed — Bosentan tablets, updated June 2 2026 · EMA EPAR — Tracleer · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bosentan Environmental Risk Assessment (ERA) (the Bosentan ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.